Bob

[Genentech ] Genentech announced that the US FDA has accepted and granted Priority Review to its sBLA for Tecentriq® (atezolizumab) and Tecentriq Hybreza® in combination with chemotherapy for stage III dMMR/MSI-H colon cancer.

[Nature] Scientists identified dHuR as a molecular glue degrader of human antigen R (HuR), an RNA-binding protein that drives tumour growth, invasion, and therapy resistance.

[Journal of Translational Medicine] Investigators show that Sirtuin-3 (SIRT3) drives gastric cancer progression and cisplatin resistance by stabilizing the mitochondrial transporter SLC25A6, revealing a metabolic pathway that could be targeted to overcome chemoresistance.

[Msystems] Researchers demonstrated a progressive decline of harmane levels in the gut from healthy individuals to advanced adenoma and colorectal cancer (CRC) patients, suggesting its potential protective role in CRC development.

[Journal of Agricultural and Food Chemistry] The authors found that 48-week PCB138 exposure induced ileal damage, inflammation, oxidative stress, and necroptosis in mice, which were mitigated by theabrownin intervention.

[Journal of Enzyme Inhibition and Medicinal Chemistry] Scientists systematically evaluated the effects of combining lidocaine with sorafenib and/or GW5074 in colorectal cancer cell lines. They aimed to determine whether these regimens enhance cytotoxicity, overcome resistance associated with targeted therapies, and modulate cell death pathways.